Spotlight on Cancer Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of São Paulo, is a state institution that will care for cancer patients from São Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of São Paulo.

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of So Paulo, is a state institution that will care for cancer patients from So Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of So Paulo.

The new cancer center is named after Octavio Frias de Oliveira, who built a media empire in Brazil and was publisher of Folha de So Paulo, Brazil’s largest newpaper. Mr. Frias died last year at age 94.

Managed by medical school


With 580 beds, the new hospital will be managed by The Medical School of the University of So Paulo, the premier medical school in Brazil.

The Institute will focus on medical care, education, and research. The objective is to position the Institute as one of the main research centers in the world. 

When operating at full capacity, it is estimated that the Institute will deliver care to approximately 16,000 new patients every year. It occupies a 28-floor building, with 540,000 square feet dedicated to cancer care and research.

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content